Pay in 4 interest-free payments of $5.67 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
For a listing of toxin-free cleaning products, please visit EWG
Action Step: Increase your intake of lean meats, Greek yogurt, legumes, and cruciferous vegetables on days five, six, and seven
As with all medical weight-loss treatments, you should thoroughly consider the risks before deciding on an avenue
In the coming weeks, Novo Nordisk is expected to release fresh Phase III data for its next-generation weight loss treatment CagriSema, which analysts say could be the next big thing in the obesity space
Choose Polar Bear Meds for your Saxenda purchase and experience the convenience, affordability, and reliability you deserve
Apitegromab: Phase 3 SAPPHIRE in SMA# The Phase 3 SAPPHIRE trial represents the most advanced clinical success for any myostatin-targeted therapy: 188 patients aged 2-21 with Type 2 or 3 SMA, all receiving background SMN-targeted treatment Primary endpoint met : Clinically meaningful improvement on HFMSE (Hammersmith Functional Motor Scale Expanded) versus placebo (p=0.0192), with a mean difference of 1.8 points Functional responders : 30.4% of apitegromab patients achieved 3 or more point HFMSE improvement versus 12.5% placebo Upper limb function : Consistent improvement measured by RULM (Revised Upper Limb Module) Published in The Lancet Neurology This is notable because it overcomes the historical "mass-function disconnect" that plagued earlier myostatin inhibitors -- apitegromab improved actual motor function, not just muscle mass
